NanoViricides, Inc. (NNVC) News
Follow NanoViricides, Inc. (NNVC) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 20 public stories across 11 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Anil R. Diwan extended as President; Meeta Vyas reappointed as CFO at Nanoviricides
Nanoviricides extended Anil R. Diwan's employment as President through June 30, 2027 and renewed Meeta Vyas as Chief Financial Officer for the same period, effective July 1, 2026.Original SEC Filing: NANOVIRICIDES, INC.
REGULATION | Sep 29, 2026, 08:33 PM UTC
L
NanoViricides, Inc. (NNVC) Files FY2026 10-K; NV-387 Phase II Trials Begin Enrollment
NanoViricides filed its FY2026 Form 10-K and said NV-387 oral gummies Phase II trials for Mpox and Ebola in DRC began enrolling at end-Sept. 2026. Cash was approximately $2.79M at June 30, 2026; substantial doubt exists
NEWS | Sep 29, 2026, 12:48 PM UTC
L
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials
SHELTON, CT / / September 29, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2026 with the Securities and Exc
REGULATION | Sep 29, 2026, 12:48 PM UTC
L
NANOVIRICIDES, INC. FY 2026: Revenue $0 EPS ($0.41) — 10-K Summary
NANOVIRICIDES, INC. reported fiscal 2026 results in its 10-K showing no revenue for the year and a net loss of $8.22M, an improvement from a $9.47M loss in FY 2025; diluted loss per share was $0.41 in FY 2026 versus $0.6
EARNINGS | Sep 28, 2026, 08:37 PM UTC
L
NanoViricides, Inc. (NNVC) Starts Phase II Trial of Oral NV-387 for Ebola
NanoViricides began enrolling and dosing patients in a Phase IIA/IIB trial of its oral NV-387 gummies for Ebola in the DRC, with dosing started on or about Sept. 23, 2026.Material DetailsContext by AI AnalystThis is an e
NEWS | Sep 28, 2026, 12:48 PM UTC
L
Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides
SHELTON, CT / / September 28, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that its Phase II Clinical Trial of
NEWS | Sep 28, 2026, 12:48 PM UTC
L
NanoViricides (NNVC) Starts Phase II Trial of NV-387 for Mpox in DRC
NanoViricides began patient enrollment in a Phase II (IIa/IIb), open-label, randomized trial of oral NV-387 for mpox in the Democratic Republic of Congo, evaluating efficacy and safety versus standard of care.Material De
NEWS | Sep 23, 2026, 12:32 PM UTC
L
Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
SHELTON, CT / / September 23, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that the Phase II Clinical Trial of the Company's Novel Broad-Spectrum Antiviral Drug NV-387 as a Treatment fo
NEWS | Sep 23, 2026, 12:31 PM UTC
L
NNVC - Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
NNVC - Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
NEWS | Sep 23, 2026, 12:30 PM UTC
L
NanoViricides (AMEX:NNVC) To Start Phase II Oral Ebola Trial in DRC Next Week
NanoViricides, Inc. said a Phase IIA/IIB trial of oral NV-387 gummies for Ebola is scheduled to start next week at an Ebola Treatment Center in Ituri province, DRC.Material DetailsContext by AI AnalystThis is an early-to
NEWS | Sep 15, 2026, 01:31 PM UTC
L
Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48% Crude Fatality Rate, Says NanoViricides
SHELTON, CT / / September 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that its Phase II Clinical Trial of
CENTRAL_BANK | Sep 15, 2026, 01:31 PM UTC
L
NNVC - Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48% Crude Fatality Rate, Says NanoViricides
NNVC - Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48% Crude Fatality Rate, Says NanoViric
CENTRAL_BANK | Sep 15, 2026, 01:25 PM UTC
L
NanoViricides registers Phase II NV-387 oral trial in Pan African database
NanoViricides (NNVC) said its Phase II clinical trial of NV-387 oral gummies to treat the current Bundibugyo Ebola outbreak has been registered in the Pan African Clinical Trials Database and is ready to go.
EQUITY | Sep 08, 2026, 12:30 PM UTC
H
NNVC plans Phase II trial of NV-387 oral gummies in DR Congo
NNVC says a Phase II clinical trial of NV-387 oral gummies as a treatment for Ebola in DR Congo is set to begin soon.
EQUITY | Aug 18, 2026, 12:30 PM UTC
L
NNVC NanoViricides prices offering with 2,516,339 warrants at US$ 1.75 exercise price
NNVC NanoViricides prices offering with 2,516,339 warrants at US$ 1.75 exercise price
EQUITY | Jul 24, 2026, 12:10 PM UTC
L
NNVC nanoviricides, Inc: sufficient quantity of NV-387 oral gummies drug product for starting clinical trial against ebola is already availa
NNVC nanoviricides, Inc: sufficient quantity of NV-387 oral gummies drug product for starting clinical trial against ebola is already available in drc
EQUITY | Jul 22, 2026, 12:33 PM UTC
L
NanoViricides initiated with bullish view at Noble Capital, here's why
Noble Capital initiated...
EQUITY | Jul 06, 2026, 01:30 PM UTC
L
NanoViricides Continues To Advance Broad-Spectrum Antiviral Drug NV-387 Towards Phase II Clinical Trial Of NV-387 Oral Gummies Formulation A
NanoViricides, Inc. (NYSE: NNVC ) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, updates that it has continued to advance its broad-spectrum antiviral drug NV-387 towards
EQUITY | Jul 06, 2026, 12:40 PM UTC
M
FDA's Office Of Orphan Products Development Grants Rare Pediatric Disease Drug Designation To NanoViricides' Antiviral Drug NV-387
NanoViricides, Inc., a publicly traded company (NYSE American: NNVC ) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine techn
REGULATION | Jun 29, 2026, 12:40 PM UTC
M
NNVC Ships Monkeypox Treatment
NanoViricides ships NV-387 oral gummies to the Democratic Republic of Congo for its Phase II clinical trial of monkeypox treatment
EQUITY | Jun 22, 2026, 01:35 PM UTC